 Transgenic non-human animals for producing heterologous antibodies |
| As has been discussed supra, it is desirable to produce human immunoglobulins that are reactive ... |
|
| Nucleic acids encoding lymphoid CD30 antigen |
| We claim: 1. An isolated nucleic acid molecule comprising a polynucleotide having a sequence ... |
|
| Feeding tray for multiwell test apparatus |
| This invention will be described herein with reference to the growing and use of cells on a ... |
|
| Neo-tryptophan |
| What is claimed is: 1. A method of making a neurotensin polypeptide containing neo-tryptophan, said ... |
|
| Human immunodeficiency virus decoy |
| OF THE INVENTION The present invention has wide application to immunologic procedures and methods ... |
|
| Capsid forming and cystein modified chimaeric MS2-coat protein |
| We claim: 1. A modified coat protein capable of forming a capsid which comprises the coat protein ... |
|
| Strategically modified hepatitis B core proteins and their derivatives |
| The present invention relates to a strategically modified hepatitis B core (HBc) protein that is ... |
|
| Chimeric biotin-binding papillomavirus protein |
| OF THE INVENTION The first domain of the chimeric protein includes at least a portion of a ... |
|
|
Method for the culture of microorganisms of the genera helicobacter, campylobacter and arcobacter employing culture media comprising cyclodextrins
| Details |
Inventors: Figura, Natale; Bugnoli, Massimo; Olivieri, Roberto; Rappuoli, Rino;
Assignee: Chiron S.p.A. (IT)
Primary Examiner: Prats; Francisco C.
Assistant Examiner:
Attorney, Agent or Firm: Woodcock Washburn Kurtz Mackiewicz & Norris, LLP, Harbin; Alisa A., Blackburn; Robert P.
Method for the culture of microorganisms of the genera Helicobacter, Campylobacter and Arcobacter, wherein culture media are employed, which comprise, in place of blood or its derivative, cyclodextrins. |
|
DETAILED DESCRIPTION It has been surprisingly discovered, and it makes the object of the present invention, that culture media wherein blood and its derivatives are, at least partially, replaced by cyclodextrins, enable the microorganisms of the genera Helicobacter, Campylobacter and Arcobacter to be cultivated in a similar way and with yield even improved over those obtained with the traditional media.
The present invention therefore relates to a method for the culture of microorganisms of the genera Helicobacter, Campylobacter and Arcobacter with the object of preparing the cell layer of the same microorganisms and/or the specific proteins of pharmaceutical interest produced by the same or still for manufacturing cheap culture media suitable for the primary isolation of microorganisms belonging to the aforementioned genera.
According to a specific embodiment of the present invention said culture method relates to the culture of microorganisms selected from the group consisting of Camplylobacter jejuni, Campylobacter coli, Campylobacter laridis, Campylobacter jejuni subspecies doylei, Campylobacter upsaliensis, Campylobacter hyointestinalis, Campylobacter fetus subspecies fetus, Campylobacter fetus subspecies venerealis, Campylobacter fennelliae, Campylobacter sputorum subspecies bubulus, Campylobacter sputorum subspecies fecalis, and Campylobacter concisus, Arcobacter nitrofigilis, Arcobacter cryaerophilus, and Arcobacter butzleri.
More specifically the invention relates to a method for the culture of Helicobacter pylori, and to the production of the about 130 kD (128 kD) protein associated to the cytotoxic activity, the protein exhibiting ureasic activity synthesized by the same microorganism, and the about 90 kD protein associated to vacuolating activity (VacA).
The about 130 kD protein is the immunodominant surface exposed antigen of H.
pylori.
According to a still more specific embodiment of the present invention, blood and/or derivatives thereof are entirely absent from the culture media
|
| Related patents |
|
|
Purified vacuolating toxin from Helicobacter pylori and methods to use same
It is an object of the present invention to provide a substantially pure antigenic composition with vacuolating toxin activity. It is an object of the present invention ...
|
|
|
Process for preparation of a microbial agent
I claim: 1. A microbial control agent made by the process of: isolating Chilodonella uncinata; colonizing Chilodonella uncinata under laboratory conditions using ...
|
|
|
Product of infectious respiratory syncytial virus from cloned nucleotide sequences
The present invention provides an isolated infectious RSV particle which comprises a recombinant RSV genome or antigenome, a nucleocapsid (N) protein, a nucleocapsid ...
|
|
|
Protein tyrosine kinase substrate LAT and its use in the indentification of (ant)agonists of the kinase
OF SPECIFIC EMBODIMENTS Generally, the nomenclature used hereafter and the laboratory procedures in cell culture, molecular genetics, and nucleic acid chemistry and ...
|
|
|
Biodegradable and biocompatible polymeric microspheres encapsulating Salmonella enteritidis bacteria
In accordance with the present invention, there are provided long term release, biocompatible and biodegradable, porous, polymeric microcapsules comprising whole killed S...
|
|
|
Method for producing yeast expressed HPV types 6 and 16 capsid proteins
What is claimed is: 1. A virus-like particle (VLP) comprising a first late 1 (L1) capsid protein from human papilloma virus (HPV) type 6 and a second L1 capsid protein ...
|
|
|
Exchangeable template reaction
OF THE INVENTION Description of the Exchangeable Template Reaction (ETR) mechanism. The ETR is a method for the synthesis of long polynucleotide DNA fragments using ...
|
|
|
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
As has been discussed supra, it is desirable to produce human immunoglobulins that are reactive with specific human antigens that are promising therapeutic and/or ...
|
|
|
Transgenic non-human animals capable of producing heterologous antibodies
The design of a transgenic non-human animal that responds to foreign antigen stimulation with a heterologous antibody repertoire, requires that the heterologous ...
|
|
|
Transgenic non-human animals capable of producing heterologous antibodies
As has been discussed supra, it is desirable to produce human immunoglobulins that are reactive with specific human antigens that are promising therapeutic and/or ...
|
|
|
Drugs 
